Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor

摘要

Ornithine decarboxylase inhibitors when administered in conjunction with autologous LAK cells and interleukin-2 provide for an enhanced treatment of neoplastic disease states. This enhancement is provided by the ability of an ornithine decarboxylase inhibitor to reduce tumor load and to enhance interleukin-2 production in T helper cells.